bioAffinity Technologies, Inc. Net Change in Cash
bioAffinity Technologies, Inc. (BIAF) reported Net Change in Cash of -$4.02 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-07
- bioAffinity Technologies, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$3.35M.
- bioAffinity Technologies, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$660.59K.
- bioAffinity Technologies, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$368.40K.
- bioAffinity Technologies, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$1.64M.
- bioAffinity Technologies, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $5.34M.
- bioAffinity Technologies, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$1.72M.
- bioAffinity Technologies, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$8.59M, a 185.47% decline from fiscal 2022.
- bioAffinity Technologies, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was $10.05M, a 686.92% increase from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$4.02M 10-Q · filed 2026-08-07 | |||
| 2026-03-31 | -$3.35M 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | $5.34M 10-K · filed 2026-03-16 | |||
| 2025-09-30 | $6.56M 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | -$302.46K 10-Q · filed 2026-08-07 | |||
| 2025-03-31 | -$660.59K 10-Q · filed 2026-05-11 | |||
| 2024-12-31 | -$1.72M 10-K · filed 2026-03-16 | |||
| 2024-09-30 | -$2.06M 10-Q · filed 2025-11-14 | |||
| 2024-06-30 | -$2.02M 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | -$368.40K 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | -$8.59M 10-K · filed 2025-03-31 | |||
| 2023-09-30 | -$6.90M 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | -$3.13M 10-Q · filed 2024-08-14 | |||
| 2023-03-31 | -$1.64M 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | $10.05M 10-K · filed 2024-04-01 | |||
| 2022-09-30 | $12.14M 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | -$1.15M 10-Q · filed 2023-08-14 | |||
| 2022-03-31 | -$332.60K 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | $1.28M 10-K · filed 2023-03-31 | |||
| 2021-09-30 | $160.72K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |